[Short QT syndrome].

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Short QT syndrome (SQTS) is a rare genetic disorder linked to familial atrial fibrillation and sudden cardiac death.
• Mutations in genes KCNH2, KCNQ1, and KCNJ2, encoding cardiac ion channels, are identified causes of SQTS.
• These mutations result in a gain-of-function of ion currents (IKr, IKs, IK1), leading to a shortened cardiac action potential.

Purpose of the Study:

• To describe the genetic basis and clinical phenotype of Short QT syndrome.
• To evaluate the effectiveness of current therapeutic strategies, including implantable cardioverter defibrillators and pharmacological interventions.

Main Methods:

• Genetic analysis of patients with familial atrial fibrillation and/or sudden death.
• Clinical phenotyping including ECG measurements (QT interval, heart rate adaptation) and electrophysiological studies.
• Assessment of drug efficacy (sotalol, ibutilide, quinidine) on QT interval and refractory periods in affected individuals.

Main Results:

• SQTS is characterized by a significantly shortened QT interval (<335 ms) with poor heart rate adaptation.
• Patients exhibit shortened atrial and ventricular effective refractory periods and inducible ventricular fibrillation.
• Implantable cardioverter defibrillators are the primary therapy due to high sudden death incidence; quinidine shows potential in prolonging QT intervals and normalizing refractory periods.

Conclusions:

• Short QT syndrome is a severe genetic disorder with a high risk of sudden cardiac death, particularly in newborns.
• Standard antiarrhythmic drugs may be ineffective; quinidine demonstrates therapeutic potential for managing QT interval prolongation and refractory period normalization.
• Further research into targeted pharmacological therapies is warranted for effective management of SQTS.